Rexin G is a tumor-targeted genetic medication for cancer. Its primary mechanism is a retrovector bearing a cytocidal cyclin G1 construct, which is a form of targeted gene therapy vector used to get a fast track orphan drug priority for multiple cancer indications within the United States. After phase one and two clinical trials, the drug has been shown to effectively shrink metastatic tumors and triple the survival times of chemotherapy-resistant pancreatic cancers. Recent studies have also confirmed the overall safety of the Rexin G drug and have shown that Rexin-G monotherapy, at the recommended dose levels, exhibits significant anti-tumor activity and increases both overall survival time and the survival rates in the majority of patients.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
CAS number |
|
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |